Symphony’s Strategic Advisory Committee is comprised of leaders from some of the most successful biopharmaceutical companies and medical research institutions in the world. The Committee’s role is to provide overall strategic input and selectively assist with the investment process. The members of the Strategic Advisory Committee are compensated for their services by Symphony and will also participate in Fund II through an economic interest in the General Partner.
Symphony also accesses a deep network of leading physicians, scientists and other experts who selectively participate in aspects of the investment process. Most are affiliated with major academic institutions or have particular expertise and experience pertinent to biopharmaceutical product development or the FDA regulatory process. Many of these individuals have worked with Symphony on Fund I investments.
Sam L. Barker, Ph.D.
Dr. Barker worked in the health sciences and pharmaceutical arenas at Bristol-Myers Squibb for over 35 years, retiring in 1999. At Bristol-Myers Squibb, he gained broad experience in R&D, manufacturing, business development, sales and marketing. After the merger of Bristol-Myers and Squibb in 1989, he assumed the position of Vice President, Asia/Pacific for the Pharmaceutical Group, and in 1991 he was appointed President, Intercontinental, Bristol-Myers Squibb Company. In 1992, Dr. Barker was appointed President, U.S. Pharmaceuticals. Dr. Barker is a co-founder of Clearview Projects, Inc., a transaction-oriented company that assists biotechnology companies in partnering their products and technologies. He serves on the Board of Directors of Atherogenics, Inc., Cadence Pharmaceuticals, Inc. and Lexicon Pharmaceuticals, Inc., where he also serves as Chairman. Dr. Barker is a graduate of Henderson State College and the University of Arkansas and has a Ph.D. in Bionucleonics from the School of Pharmacy at Purdue University.
Stelios Papadopoulos, Ph.D.
Dr. Papadopoulos’ career in biopharmaceuticals spans more than two decades. Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in August 2006 after six years with the firm where, as an investment banker, he focused on the biopharmaceutical sector. Prior to joining Cowen, he spent thirteen years as an investment banker at PaineWebber, Inc., where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert, where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette.
Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with NYU Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University.
Dr. Papadopoulos is a co-founder and Chairman of the Board of Directors of Exelixis, Inc., and he is a co-founder and member of the Board of both Anadys Pharmaceuticals, Inc. and Cellzome, Inc. He is Vice Chairman of the Board of Directors of BG Medicine, Inc. and a member of the Board of Directors of Neuronyx, Inc. In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé, a member of the Board of Visitors of Duke University Medical Center and a member of the Board of Directors of the National Marrow Donor Program.
Bruce Stillman, AO, FRS, Ph.D.
Dr. Stillman is President and Chief Executive Officer of Cold Spring Harbor Laboratory on the north shore of Long Island in New York. A native of Australia, he obtained a B.S. degree with honors at Sydney University and a Ph.D. at the John Curtin School of Medical Research at the Australian National University. He then moved to Cold Spring Harbor Laboratory as a Postdoctoral Fellow in 1979 and has been at the Laboratory ever since, being promoted to the scientific staff in 1981. Dr. Stillman has been Director of the Cancer Center at Cold Spring Harbor Laboratory since 1992, a position he still holds. In 1994 he succeeded Dr. James D. Watson as Director of Cold Spring Harbor Laboratory, and in 2003 was named its President. Dr. Stillman’s research focuses on understanding how genomes are duplicated prior to cell division.
For his research accomplishments, Dr. Stillman has received a number of honors including election as a Fellow of The Royal Society in 1993. In 1994 Dr. Stillman was awarded the Julian Wells Medal (Australia) and in 1995 he was elected a Charter Fellow of the Molecular Medicine Society. In 1999 Dr. Stillman was appointed an Officer of the Order of Australia (AO) for service to scientific research in the field of molecular biology. Dr. Stillman was elected in 2000 to the U.S. National Academy of Sciences and in 2001 was elected as Foreign Associate of the European Molecular Biology Organization. In addition to five honorary doctorates, he received the Alfred Sloan Prize for cancer research in 2004 and the Curtin Medal for Medical Excellence in 2007. He is an advisor to a number of academic and commercial organizations.
Douglas E. Williams, Ph.D.
Dr. Williams currently serves as Executive Vice President, Research and Development for Biogen Idec, a position he has held since January 2011. Previously, he was Chief Executive Officer of ZymoGenetics and as a member of the company's Board of Directors. Dr. Williams has held senior level positions at a number of biotechnology companies, including Seattle Genetics, Genesis Research, Immunex and Amgen. As Executive Vice President and Chief Technology Officer at Immunex, Dr. Williams played a significant role in the discovery and early development of Leukine, a white blood cell growth factor, and Enbrel, the first biologic approved for the treatment of rheumatoid arthritis. In addition, Dr. Williams was a member of Immunex Corporation’s Board of Directors.
Before entering the biotechnology industry, Dr. Williams served on the faculty of the Indiana University School of Medicine and worked in the Department of Laboratory Medicine at the Roswell Park Memorial Institute in Buffalo, NY. He earned a B.S. magna cum laude in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo. Dr. Williams is the author of over 100 articles focused on hematology, cytokine biology and immunology.
In addition to his role at ZymoGenetics, Dr. Williams serves on the Board of Directors of Anadys Pharmaceuticals, Aerovance and Array Biopharma. He is also a member of the Board of Trustees at the Fred Hutchinson Cancer Research Center.